Reported Earlier, Rain Oncology To Be Acquired By Pathos AI For $1.16/Share Plus Additional Contingent Value Rights
Pursuant and subject to the terms of the merger agreement, a subsidiary of Pathos will commence a tender offer to acquire all outstanding shares of Rain for $1.16 in cash per share plus a CVR representing a